Study: NCT03219008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine is one kind of selective serotonin reuptake inhibitor(SSRIs), whose effect is much better than other non-underload subtypes compared with underload subtypes.So patients would be treated with fluoxetine only.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: fluoxetine + cognitive-behavioral treatment（CBT）
Description: the investigators would recommend fluoxetine to help to cure depressive disorder.And CBT is a very effective way for patients to alleviate or relieve clinical symptoms during episode stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine + Amfebutamone
Description: Amfebutamone is one kind of SNRIs, and it shows much better therapy effect on patients with exhaustion /dizziness.So the investigators recommend these two drugs to help to cure patients with depressive disorder.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: physical treatment+fluoxetine+amfebutamone
Description: the investigators recommend drug(fluoxetine and amfebutamone) and physical treatment as intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine could inhibit CYP1A2 and CYP2C19 and affect the metabolism of melatonin, and help to release symptoms of depressive disorder with sleep problems.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium+fluvoxamine
Description: the investigators recommend lithium as a mood stabilizer and use fluvoxamine to affect the level of melatonin.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: fluvoxamine + lithium + physical therapy
Description: the investigators recommend depressants and mood stabilizers as well as physical therapy to help to cure depressive disorder.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cognitive behavior treatment +fluvoxamine
Description: the investigators recommend behavioral therapy as well as drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine/SNRIs
Description: Mirtazapine is one kind of antagonist of a2 adrenergic receptors and could block 5-hydroxytryptamine2 and 5-hydroxytryptamine3,help to release symptoms like anxiety or somatization.Besides, SNRIs could also make similar effect on patients.Therefore, the investigators recommend mirtazapine/SNRIs to treat patients with depressive disorder.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: mirtazapine+ Cognitive behavior treatment
Description: the investigators recommend CBT and mirtazapine as interventions.The dosage and frequency would depend on patients' severity of symptoms .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirtazapine + SNRIs
Description: the investigator recommend mirtazapine and SNRIs to treat patients with major depressive disorder.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: mirtazapine + SNRIs + physical therapy
Description: the investigators would manage to use drugs and physical treatment to help to release the symptoms of depressive disorder.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAU(treat as usual)
Description: patients in this group would receive therapy strategies according to their symptoms and preference.